Zimmer Biomet announced plans to continue developing its robotic platforms and investing in a stronger, specialised sales force in the US at the 2026 JP Morgan Healthcare conference. The company’s ambition is to be the most comprehensive orthopaedic company using robotics, through the ROSA system, a licensed CT-based handheld robot, mixed-reality navigation, AI-based surgical navigation, and advanced semi- and fully autonomous robotics.
According to GlobalData analysis, the surgical robotic market was valued at $10.0bn in 2025 and is projected to reach sales of $17.3bn by 2033, at a compound annual growth rate (CAGR) of 6.2%. GlobalData’s SKU Premium product indicates that the growth of orthopaedic robotics robustly increased 16.7% from 2023 to 2024 in the US. Reasons for this increase include an ageing population, more elective joint replacement procedures, and a shift toward ambulatory surgical centres (ASCs) where orthopaedic robotics can yield operational advantages. Stryker’s MAKO system currently leads adoption in the US. In July 2025, Zimmer Biomet moved decisively to acquire Monogram Technologies, obtaining semi- and fully autonomous robotic technologies, including a CT-based, AI-navigated total knee arthroplasty (TKA) system already FDA-cleared. This technology is expected to be commercialised in early 2027. Zimmer’s goal with ROSA plus Monogram is to offer more choice and recapture share through differentiated offerings.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Additionally, robotics penetration is heavily driven by training, case support, service, and utilisation management; stronger field support is a direct lever to increase placements and procedure volume per system. Beyond product and platform diversification, Zimmer Biomet expects to increase specialised sales reps by 3.5 times from 2024 through 2027 to win the share of the robotics business.
Zimmer Biomet is making a bold, multi-pronged bet to become the most comprehensive orthopaedic robotics player—blending imaging/no-imaging robotics, navigation (AI, mixed reality), and handheld and autonomous platforms. Its strategy is designed to address surgeon preferences and market segments, including those who value full autonomy, customisation, or more traditional control. Zimmer’s robotics strategy aligns with expected global market growth; success depends on execution in regulatory approvals, product launches, and sales force expansion to capture both hardware sales and higher-margin recurring revenue streams.
Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare conference 2026. Sign up here to receive a comprehensive report after the conference.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
